$3250 | Single User
$4650 | Site License
$5650 | Global License

Hepatitis Therapeutics Market, By Disease Type (Hepatitis C, Hepatitis B, Hepatitis A), By Drug Class (NS5A Inhibitor, Interferon & Ribavirin, Multi-Class Combination, Nucleotide Analog NS5B Polymerase Inhibitor), By Distribution Channel (Online, Retail, Hospital Pharmacies), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026
[Lowest Price Guaranteed: $3,250]

Published by AnalystView: 01 Jun 2020 | 270639 | In Stock
Related Topics: Agencies , COVID , Drug , Healthcare , Hepatitis , Life , Retail , Roche

Introduction

REPORT HIGHLIGHT

Hepatitis therapeutics market was valued at USD 21.86 billion by 2019, growing with 2.6% CAGR during the forecast period, 2020-2026.

Hepatitis can be defined as an inflammation of the liver, which is caused due to a viral infection. It is one of the leading causes of health care burden in both developing as well as developed countries. Hepatitis can progress to scarring (fibrosis), cirrhosis, liver cancer or it can be self-limiting. The major causes of hepatitis are hepatitis viruses and the heavy consumption of alcohol, which affects the liver. However, autoimmune diseases and toxic substances can also cause hepatitis.

Market Dynamics

The rising prevalence of viral hepatitis, an increase in healthcare expenditure, and a surge in the number of autoimmune diseases are the major factors boosting the growth of the global hepatitis therapeutics market. According to the statistics provided by the World Health Organization (WHO), around 325 million people were diagnosed with viral hepatitis worldwide in 2016 and this number is expected to increase by 2030. Moreover, the growing usage of infected syringes and unsterilized equipment, transfusion of infectious blood, and medication errors are other factors propelling the market growth.

In addition, high success rates of pipeline drugs, the increase in consumption of alcohol, and the growing incidence of liver diseases will impel the market growth in upcoming years. However, high development costs and stringent reimbursement policies are predicted to hinder the growth of the global market. On the contrary, the growing development in advanced therapies and increasing focus towards retaining the best quality life are expected to create lucrative growth opportunities in the overall market during the forecast period.

Disease Type Takeaway

“Hepatitis B segment to be most lucrative during the forecast period”

Based on the disease type, the global market for hepatitis therapeutics is categorized into hepatitis A, B, and C. Among these, the hepatitis B (HBV) segment accounted for the majority of market share in 2019 and is expected to lead the market during the forecast period. This is majorly because the virus can be easily transmitted through body fluids and blood of an infected person. The prevalence of hepatitis B is high all across the globe, which is driving the segmental market growth. According to the WHO, around 27 million people all across the globe were aware of HBV infection, of which 4.5 million diagnosed were on treatment in 2016.

On the other hand, the hepatitis C (HCV) segment is estimated to grow at a considerable rate during the forecast period due to the growing prevalence of liver diseases all over the world. WHO statistics reveal that about 71 million people worldwide were living with the HCV infection in 2016.

Drug Class Takeaway

“Multi-class combination segment to dominate the industry by 2026”

On the basis of drug class, the worldwide hepatitis therapeutics market is categorized into NS5A inhibitor, interferon & ribavirin, multi-class combination, and nucleotide analog NS5B polymerase inhibitor. Of these, the NS5A inhibitor accounted for the largest market share in 2019 and is anticipated to grow at a significant rate during the forecast period. This is mainly because it is the most common drug used for the treatment of viral hepatitis. In addition, the increasing consumption of alcohol is resulting in liver diseases, which is resulting in increased demand for NS5A inhibitor all across the globe. On the other hand, the multi-class combination segment is estimated to grow at a significant rate during the forecast period owing to its favorable features such as effectiveness across the genotypes of Hepatitis C.

Distribution Channel

“Hospital pharmacies segment to grow at a significant rate throughout the forecast”

Based on the distribution channel, the worldwide hepatitis therapeutics market is classified into online pharmacies, retail pharmacies, and hospital pharmacies. Of these, the hospital pharmacies segment is estimated to lead the market during the forecast period. The dominance of this segment is mainly because the dispensations of drugs at these pharmacies ensure a greater deal of safety. On the other hand, the retail pharmacies segment is estimated to be the second-largest market at a significant rate during the forecast period.

COVID-19 Impact

The emergence of the life-threatening COVID-19 has brought the world to a halt. This health crisis has brought an uncertain impact on businesses across various industries. The global hepatitis therapeutic market is adversely affected due to the COVID-19 pandemic. However, the rising support from governments and various strategies adopted by the companies is helping to fight against this highly contagious disease. The overall market is expected to witness an impressive growth post the coronavirus pandemic.

Key Vendor Takeaway

The leading players of the global hepatitis therapeutics market include Merck, Johnson & Johnson, Biocon, Bristol-Myers Squibb Co, Gilead Lifesciences, NATCO Pharma Limited, ZydusCadila, Hetero Healthcare, Roche Diagnostics, LAURUS Labs, Cipla, Inc., and AbbVie.

In November 2019, Gilead Sciences announced new data from the Viral Hepatitis Research Programs at The Liver Meeting.® The new data of the Vemlidy® (tenofovir alafenamide 25 mg, TAF) continues to support an enhanced safety profile compared with tenofovir disoproxil fumarate (TDF) in patients with chronic HBV (Hepatitis B) infection.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2015 to2018

Base Year – 2019

Estimated Year – 2020

Projected Year – 2026

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Government and Regional Agencies

Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HEPATITIS THERAPEUTIC MARKET KEY PLAYERS

NATCO Pharma Limited

ZydusCadila

Hetero Healthcare

Merck & Co.

Gilead Lifesciences

Roche Diagnostics

LAURUS Labs

Cipla, Inc.

Johnson & Johnson

Biocon Limited

Bristol-Myers Squibb Co

AbbVie, Inc.

GLOBAL HEPATITIS THERAPEUTIC MARKET, BY DISEASE TYPE

Hepatitis A

Hepatitis B

Hepatitis C

Others

GLOBAL HEPATITIS THERAPEUTIC MARKET, BY DRUG CLASS

Nucleotide Analog NS5B Polymerase Inhibitor

NS5A Inhibitor

Multi-Class Combination

Interferon & Ribavirin

Others

GLOBAL HEPATITIS THERAPEUTIC MARKET, BY DISTRIBUTION CHANNEL

Online Pharmacies

Retail Pharmacies

Hospital Pharmacies

GLOBAL HEPATITIS THERAPEUTIC MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

The Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

Table of Contents
for Hepatitis Therapeutics Market, By Disease Type (Hepatitis C, Hepatitis B, Hepatitis A), By Drug Class (NS5A Inhibitor, Interferon & Ribavirin, Multi-Class Combination, Nucleotide Analog NS5B Polymerase Inhibitor), By Distribution Channel (Online, Retail, Hospital Pharmacies), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

  • TABLE OF CONTENT

    1. HEPATITIS THERAPEUTICS MARKET OVERVIEW

    1.1. Study Scope

    1.2. Assumption and Methodology

    2. EXECUTIVE SUMMARY

    2.1. Market Snippet

    2.1.1. Market Snippet by Disease Type

    2.1.2. Market Snippet by Drug Class

    2.1.3. Market Snippet by Distribution Channel

    2.1.4. Market Snippet by Region

    2.2. Competitive Insights

    3. HEPATITIS THERAPEUTICS KEY MARKET TRENDS

    3.1. Market Drivers

    3.1.1. Impact Analysis of Market Drivers

    3.2. Market Restraints

    3.2.1. Impact Analysis of Market Restraints

    3.3. Market Opportunities

    3.4. Market Future Trends

    4. HEPATITIS THERAPEUTICS INDUSTRY STUDY

    4.1. Porter’s Five Forces Analysis

    4.2. Marketing Strategy Analysis

    4.3. Growth Prospect Mapping

    4.4. Regulatory Framework Analysis

    4.5. COVID-19 Impact Analysis

    4.5.1. Pre-COVID-19 Impact Analysis

    4.5.2. Post-COVID-19 Impact Analysis

    5. HEPATITIS THERAPEUTICS MARKET LANDSCAPE

    5.1. Market Share Analysis

    5.2. Key Innovators

    5.3. Breakdown Data, by Key manufacturer

    5.3.1. Established Player Analysis

    5.3.2. Emerging Player Analysis

    6. HEPATITIS THERAPEUTICS MARKET – BY DISEASE TYPE

    6.1. Overview

    6.1.1. Segment Share Analysis, By Disease Type, 2019 & 2026 (%)

    6.2. Hepatitis A

    6.2.1. Overview

    6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.3. Hepatitis B

    6.3.1. Overview

    6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.4. Hepatitis C

    6.4.1. Overview

    6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.5. Others

    6.5.1. Overview

    6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    7. HEPATITIS THERAPEUTICS MARKET – BY DRUG CLASS

    7.1. Overview

    7.1.1. Segment Share Analysis, By Drug Class, 2019 & 2026 (%)

    7.2. Multi-Class Combination

    7.2.1. Overview

    7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    7.3. NS5A Inhibitor

    7.3.1. Overview

    7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    7.4. Interferon & Ribavirin

    7.4.1. Overview

    7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    7.5. Nucleotide Analog NS5B Polymerase Inhibitor

    7.5.1. Overview

    7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    7.6. Others

    7.6.1. Overview

    7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    8. HEPATITIS THERAPEUTICS MARKET – BY DISTRIBUTION CHANNEL

    8.1. Overview

    8.1.1. Segment Share Analysis, By Distribution Channel, 2019 & 2026 (%)

    8.2. Online Pharmacies

    8.2.1. Overview

    8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    8.3. Retail Pharmacies

    8.3.1. Overview

    8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    8.4. Hospital Pharmacies

    8.4.1. Overview

    8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9. HEPATITIS THERAPEUTICS MARKET– BY GEOGRAPHY

    9.1. Introduction

    9.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)

    9.2. North America

    9.2.1. Overview

    9.2.2. Key Manufacturers in North America

    9.2.3. North America Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.2.4. North America Market Size and Forecast, By Disease Type, 2015 – 2026 (US$ Million)

    9.2.5. North America Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)

    9.2.6. North America Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.2.7. U.S.

    9.2.7.1. Overview

    9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.2.8. Canada

    9.2.8.1. Overview

    9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3. Europe

    9.3.1. Overview

    9.3.2. Key Manufacturers in Europe

    9.3.3. Europe Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.3.4. Europe Market Size and Forecast, By Disease Type, 2015 – 2026 (US$ Million)

    9.3.5. Europe Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)

    9.3.6. Europe Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.3.7. Germany

    9.3.7.1. Overview

    9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3.8. Italy

    9.3.8.1. Overview

    9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3.9. United Kingdom

    9.3.9.1. Overview

    9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3.10. France

    9.3.10.1. Overview

    9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3.11. Rest of Europe

    9.3.11.1. Overview

    9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4. Asia Pacific (APAC)

    9.4.1. Overview

    9.4.2. Key Manufacturers in Asia Pacific

    9.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.4.4. Asia Pacific Market Size and Forecast, By Disease Type, 2015 – 2026 (US$ Million)

    9.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)

    9.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.4.7. India

    9.4.7.1. Overview

    9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4.8. China

    9.4.8.1. Overview

    9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4.9. Japan

    9.4.9.1. Overview

    9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4.10. South Korea

    9.4.10.1. Overview

    9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4.11. Rest of APAC

    9.4.11.1. Overview

    9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.5. Latin America

    9.5.1. Overview

    9.5.2. Key Manufacturers in Latin America

    9.5.3. Latin America Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.5.4. Latin America Market Size and Forecast, By Disease Type, 2015 – 2026 (US$ Million)

    9.5.5. Latin America Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)

    9.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.5.7. Brazil

    9.5.7.1. Overview

    9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.5.8. Mexico

    9.5.8.1. Overview

    9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.5.9. Argentina

    9.5.9.1. Overview

    9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.5.10. Rest of LATAM

    9.5.10.1. Overview

    9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.6. Middle East and Africa

    9.6.1. Overview

    9.6.2. Key Manufacturers in Middle East and Africa

    9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.6.4. Middle East and Africa Market Size and Forecast, By Disease Type, 2015 – 2026 (US$ Million)

    9.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2015 – 2026 (US$ Million)

    9.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.6.7. Saudi Arabia

    9.6.7.1. Overview

    9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.6.8. United Arab Emirates

    9.6.8.1. Overview

    9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    10. KEY VENDOR ANALYSIS

    10.1. Merck & Co.

    10.1.1. Company Snapshot

    10.1.2. Financial Performance

    10.1.3. Disease Type Benchmarking

    10.1.4. Strategic Initiatives

    10.2. Johnson & Johnson

    10.3. Biocon Limited

    10.4. Bristol-Myers Squibb Co

    10.5. Gilead Lifesciences

    10.6. NATCO Pharma Limited

    10.7. ZydusCadila

    10.8. Hetero Healthcare

    10.9. Roche Diagnostics

    10.10. LAURUS Labs

    10.11. Cipla, Inc.

    10.12. AbbVie, Inc.

    11. 360 DEGREE ANALYSTVIEW

    12. APPENDIX

    12.1. Research Methodology

    12.2. References

    12.3. Abbreviations

    12.4. Disclaimer

    12.5. Contact Us

List Of Tables
in Hepatitis Therapeutics Market, By Disease Type (Hepatitis C, Hepatitis B, Hepatitis A), By Drug Class (NS5A Inhibitor, Interferon & Ribavirin, Multi-Class Combination, Nucleotide Analog NS5B Polymerase Inhibitor), By Distribution Channel (Online, Retail, Hospital Pharmacies), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

List of Tables

TABLE List of data sources

TABLE Market drivers; Impact Analysis

TABLE Market restraints; Impact Analysis

TABLE Hepatitis Therapeutics market: Distribution Channelnapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Disease Type

TABLE Global Hepatitis Therapeutics market, by Disease Type 2015-2026 (USD Million)

TABLE Hepatitis Therapeutics market: Drug Class Snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Drug Class

TABLE Global Hepatitis Therapeutics market, by Drug Class 2015-2026 (USD Million)

TABLE Hepatitis Therapeutics market: Distribution Channe lSnapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Distribution Channel

TABLE Global Hepatitis Therapeutics market, by Distribution Channel 2015-2026 (USD Million)

TABLE Hepatitis Therapeutics market: RegionalSnapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Region

TABLE Global Hepatitis Therapeutics market, by Region 2015-2026 (USD Million)

TABLE North America Hepatitis Therapeutics market, by Country, 2015-2026 (USD Million)

TABLE North America Hepatitis Therapeutics market, by Disease Type, 2015-2026 (USD Million)

TABLE North America Hepatitis Therapeutics market, by Drug Class, 2015-2026 (USD Million)

TABLE North America Hepatitis Therapeutics market, by Distribution Channel, 2015-2026 (USD Million)

TABLE Europe Hepatitis Therapeutics market, by Country, 2015-2026 (USD Million)

TABLE Europe Hepatitis Therapeutics market, by Disease Type, 2015-2026 (USD Million)

TABLE Europe Hepatitis Therapeutics market, by Drug Class, 2015-2026 (USD Million)

TABLE Europe Hepatitis Therapeutics market, by Distribution Channel, 2015-2026 (USD Million)

TABLE Asia Pacific Hepatitis Therapeutics market, by Country, 2015-2026 (USD Million)

TABLE Asia Pacific Hepatitis Therapeutics market, by Disease Type, 2015-2026 (USD Million)

TABLEAsia Pacific Hepatitis Therapeutics market, by Drug Class, 2015-2026 (USD Million)

TABLE Asia Pacific Hepatitis Therapeutics market, by Distribution Channel, 2015-2026 (USD Million)

TABLE Latin America Hepatitis Therapeutics market, by Country, 2015-2026 (USD Million)

TABLE Latin America Hepatitis Therapeutics market, by Disease Type, 2015-2026 (USD Million)

TABLE Latin America Hepatitis Therapeutics market, by Drug Class, 2015-2026 (USD Million)

TABLE Latin America Hepatitis Therapeutics market, by Distribution Channel, 2015-2026 (USD Million)

TABLE Middle East and Africa Hepatitis Therapeutics market, by Country, 2015-2026 (USD Million)

TABLE Middle East and Africa Hepatitis Therapeutics market, by Disease Type, 2015-2026 (USD Million)

TABLE Middle East and Africa Hepatitis Therapeutics market, by Drug Class, 2015-2026 (USD Million)

TABLE Middle East and Africa Hepatitis Therapeutics market, by Distribtion Channel, 2015-2026 (USD Million)

List Of Figures, Charts and Diagrams
in Hepatitis Therapeutics Market, By Disease Type (Hepatitis C, Hepatitis B, Hepatitis A), By Drug Class (NS5A Inhibitor, Interferon & Ribavirin, Multi-Class Combination, Nucleotide Analog NS5B Polymerase Inhibitor), By Distribution Channel (Online, Retail, Hospital Pharmacies), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

List of Figures

FIGURE Hepatitis Therapeutics market segmentation

FIGURE Market Research Methodology

FIGURE Value chain analysis

FIGURE Porter’s Five Forces Analysis

FIGURE Market Attractiveness Analysis

FIGURE COVID-19 Impact Analysis

FIGURE Pre & Post COVID-19 Impact Comparision Study

FIGURE Competitive Landscape; Key company market share analysis, 2018

FIGURE Disease Type segment market share analysis, 2019 & 2026

FIGURE Disease Type segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Hepatitis A market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Hepatitis B market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Hepatitis C market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Others market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Drug Class segment market share analysis, 2019 & 2026

FIGURE Drug Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE NS5A Inhibitor market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Interferon & Ribavirin market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Multi-Class Combination market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Nucleotide Analog NS5B Polymerase Inhibitor market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Others market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Distribution Channel segment market share analysis, 2019 & 2026

FIGURE Distribution Channel segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Online Pharmacies market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Retail Pharmacies market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Hospital Pharmacies market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Regional segment market share analysis, 2019 & 2026

FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE North America Hepatitis Therapeutics market share and leading players, 2018

FIGURE Europe Hepatitis Therapeutics market share and leading players, 2018

FIGURE Asia Pacific Hepatitis Therapeutics market share and leading players, 2018

FIGURE Latin America Hepatitis Therapeutics market share and leading players, 2018

FIGURE Middle East and Africa Hepatitis Therapeutics market share and leading players, 2018

FIGURE North America Hepatitis Therapeutics market share analysis by country, 2018

FIGURE U.S. Hepatitis Therapeutics Market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Canada Hepatitis Therapeutics Market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Europe Hepatitis Therapeutics Market share analysis by country, 2018

FIGURE Germany Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Spain Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Italy Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE UK Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE FranceHepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of the Europe Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Asia Pacific Hepatitis Therapeutics market share analysis by country, 2018

FIGURE India Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE China Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Japan Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE South Korea Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Singapore Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of APACHepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Latin America Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Latin AmericaHepatitis Therapeutics market share analysis by country, 2018

FIGURE BrazilHepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Mexico Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Argentina Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of LATAM Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Middle East and Africa Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Middle East and Africa Hepatitis Therapeutics market share analysis by country, 2018

FIGURE Saudi Arabia Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE United Arab Emirates Hepatitis Therapeutics market size, forecast and trend analysis, 2015 to 2026 (USD Million)

Additional Details

Publisher

AnalystView

Publisher Information

AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.



These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.



We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.



We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.



It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Reference

270639 | AV634

Number of Pages

187

Report Format

PDF

AnalystView Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Hepatitis Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Hepatitis C: Update Bulletin [February 2016]
IntroductionGain new KOL insights on the latest events that have the potential to shape the hepatiti...
01 Feb 2016 by FirstWord Pharma USD $995 More Info
Hepatitis C: KOL Insight
IntroductionThe Hepatitis C (HCV) market will be driven by meeting the needs of under-served patient...
01 Sep 2015 by FirstWord Pharma USD $7,900 More Info
Physician Views: The hepatitis C pricing war - what impact on prescribers?
Scope In a surprise move, AbbVie agreed last month to provide its newly approved hepatitis C drug Vi...
29 Jan 2015 by FirstWord Pharma USD $695 More Info
Payer Insights: Hepatitis C
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
26 Sep 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?
Scope Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tr...
08 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014?
Scope With this year's meeting of the International Liver Congress (EASL) just over a week away (Apr...
01 Apr 2014 by FirstWord Pharma USD $695 More Info
Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook
IntroductionThe worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?
Scope Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, inter...
01 Nov 2013 by FirstWord Pharma USD $695 More Info
Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?
ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
01 Oct 2013 by FirstWord Pharma USD $695 More Info

This report is published by AnalystView

AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.

These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.

We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.

We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.

It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Download Free Report Summary PDF

Hepatitis Therapeutics Market, By Disease Type (Hepatitis C, Hepatitis B, Hepatitis A), By Drug Class (NS5A Inhibitor, Interferon & Ribavirin, Multi-Class Combination, Nucleotide Analog NS5B Polymerase Inhibitor), By Distribution Channel (Online, Retail, Hospital Pharmacies), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...